Large Drugmakers Prioritise Faster Approvals, AI-Driven Compliance and Global Regulatory Harmonisation Amid Rising Scrutiny
Regulatory challenges have emerged as the most pressing concern for India's pharmaceutical industry, overtaking tariff uncertainties, geopolitical tensions and supply-chain dependence on China. According to Deloitte's latest Indian Pharmaceutical Industry Survey: FY27 Outlook, senior executives from leading pharmaceutical companies believe that increasingly stringent regulatory requirements and delays in product approvals will have a greater impact on business growth than global trade disruptions during FY27.
The survey, conducted among CXOs of Indian pharmaceutical companies with annual revenues exceeding ₹10,000 crore, indicates that regulatory compliance has become a strategic priority as companies expand their presence in highly regulated international markets such as the United States and Europe.
The report also highlights growing demand for artificial intelligence-based regulatory solutions, digital compliance platforms and stronger collaboration between industry and regulators to improve approval timelines and reduce operational bottlenecks.
Regulatory Scrutiny Tops the Industry's Risk List
The survey found that 57% of pharmaceutical CXOs consider increasing regulatory scrutiny across both domestic and international markets as the biggest challenge facing the industry in FY27.
Unlike external risks such as tariffs or geopolitical conflicts, regulatory actions have an immediate impact on pharmaceutical companies by influencing manufacturing approvals, plant operations, product launches and export opportunities.
Industry executives believe maintaining compliance with evolving global quality standards will remain one of the most critical success factors for Indian drug manufacturers.
Product Approval Delays Continue to Affect Growth
Another 57% of respondents identified delays in product approvals and increasing complexities surrounding clinical trials as a major business concern.
Lengthy approval processes often lead to:
-
Delayed commercial launches
-
Higher research and development costs
-
Slower revenue generation
-
Reduced competitiveness in export markets
-
Longer return on investment cycles
As Indian pharmaceutical companies continue expanding globally, faster regulatory clearances are becoming increasingly important to sustain growth.
Tariffs and Geopolitical Issues Take a Back Seat
While global trade uncertainties continue to remain relevant, executives believe they are less disruptive than regulatory challenges.
Major Business Risks Identified
| Business Challenge | Respondents Expecting Significant Impact |
|---|---|
| Regulatory scrutiny | 57% |
| Product approval delays | 57% |
| Trade and tariff disputes | 43% |
| Geopolitical tensions | 43% |
| Dependence on China | 33% |
An additional 52% of respondents described tariffs and geopolitical tensions as moderate risks rather than immediate threats.
This indicates that the pharmaceutical industry is currently more focused on operational execution than external macroeconomic uncertainties.
China Dependency Remains a Strategic Concern
Although no longer viewed as the industry's biggest challenge, dependence on Chinese imports remains an important issue.
According to the survey:
-
33% of executives consider China dependence a significant risk.
-
43% view it as a moderate concern.
Indian pharmaceutical manufacturers continue to rely on China for Active Pharmaceutical Ingredients (APIs), intermediates and other essential raw materials, prompting ongoing efforts to diversify supply chains.
Artificial Intelligence Emerging as a Regulatory Game-Changer
One of the strongest themes emerging from Deloitte's survey is the growing role of artificial intelligence in pharmaceutical regulatory processes.
As regulatory requirements become more complex across multiple jurisdictions, companies increasingly see AI as a solution for improving efficiency and reducing compliance costs.
AI-based systems can assist pharmaceutical companies by:
-
Preparing regulatory submissions
-
Automating documentation
-
Detecting compliance gaps
-
Reducing manual errors
-
Improving audit readiness
-
Accelerating approval processes
Executives believe AI has the potential to significantly modernise regulatory operations.
76% Want AI-Based Regulatory Submission Tools
Technology adoption has become a major priority for India's pharmaceutical industry.
Technology Requirements Highlighted by CXOs
| Requirement | Respondents |
|---|---|
| AI-powered regulatory submission tools | 76% |
| Unified digital approval portals | 67% |
| Faster government approvals | 62% |
| Digital compliance platforms | 48% |
| Regulatory training programmes | 14% |
The findings suggest that companies believe structural improvements and technology adoption will deliver greater benefits than additional workforce training alone.
Digital Portals Could Simplify Compliance
Nearly 67% of respondents called for integrated digital regulatory platforms that allow companies to monitor approval status, submit documents electronically and track compliance requirements in real time.
Industry executives believe digital platforms could:
-
Reduce paperwork
-
Improve transparency
-
Shorten approval timelines
-
Enhance communication with regulators
-
Lower administrative costs
-
Improve overall regulatory efficiency
Such initiatives are expected to become increasingly important as companies handle larger volumes of domestic and international filings.
Managing Multiple Global Regulatory Filings
Indian pharmaceutical companies currently navigate a complex regulatory environment involving multiple international agencies.
These include:
-
Abbreviated New Drug Applications (ANDAs) in the United States
-
Certificates of Suitability (CEP) in Europe
-
Domestic approvals in India
-
Country-specific regulatory filings across export markets
The report notes that AI-enabled systems can help prepare regulatory dossiers, eliminate duplication and ensure consistency across multiple submissions.
Industry Wants Greater Collaboration with Policymakers
Beyond technology, pharmaceutical companies are seeking closer engagement with regulators during policy formulation.
Preferred Policy Measures
-
57% support industry-government task forces for regulatory development.
-
40% favour cross-border regulatory harmonisation initiatives.
Executives believe collaborative policymaking can improve regulatory clarity while making India's pharmaceutical ecosystem more globally competitive.
Mutual Recognition Agreements Seen as Key Export Reforms
Export-oriented companies identified Mutual Recognition Agreements (MRAs) with major pharmaceutical markets as one of the most valuable policy reforms.
Approximately 71% of respondents believe agreements with markets such as the United States and the European Union would significantly improve export competitiveness.
Potential benefits include:
-
Reduced duplicate inspections
-
Faster product approvals
-
Lower compliance costs
-
Quicker market access
-
Improved operational efficiency
Such agreements could strengthen India's position as one of the world's leading suppliers of generic medicines.
Global Compliance Standards Continue to Rise
International regulators are increasingly emphasising:
-
Manufacturing quality
-
Data integrity
-
Clinical transparency
-
Pharmacovigilance
-
Digital documentation
-
Product traceability
As expectations continue to evolve, pharmaceutical companies are expected to invest heavily in digital quality systems and advanced compliance technologies.
Technology Investment Becoming a Competitive Advantage
Digital transformation is no longer viewed merely as an operational improvement—it is becoming a strategic differentiator.
Companies investing in:
-
Artificial Intelligence
-
Automation
-
Cloud-based compliance systems
-
Data analytics
-
Digital quality management
are expected to improve both regulatory efficiency and long-term profitability.
Industry experts believe technology-enabled compliance could become a decisive factor in winning contracts from regulated global markets.
Survey Highlights at a Glance
| Key Finding | Response |
|---|---|
| Regulatory scrutiny major concern | 57% |
| Product approval delays major concern | 57% |
| AI-based regulatory tools required | 76% |
| Digital approval portals preferred | 67% |
| Faster approval systems needed | 62% |
| Mutual Recognition Agreements supported | 71% |
| Industry-government policy collaboration favoured | 57% |
Implications for India's Pharmaceutical Industry
The Deloitte survey highlights a significant shift in the pharmaceutical industry's priorities, with regulatory excellence becoming as important as product innovation and manufacturing capabilities. Companies that successfully adopt AI-driven compliance systems, strengthen quality management processes and improve regulatory readiness are expected to gain a competitive advantage in highly regulated international markets. As global compliance standards continue to evolve, technology-led regulatory transformation is likely to become a key pillar of India's pharmaceutical growth strategy.
Market Outlook
India's pharmaceutical sector is expected to maintain its long-term growth trajectory, supported by strong global demand for generic medicines, specialty pharmaceuticals and contract manufacturing services. However, faster regulatory approvals, digital compliance infrastructure and greater adoption of AI-powered regulatory solutions are likely to become the next major growth drivers. Companies investing in technology, quality systems and global regulatory capabilities could be better positioned to expand exports and strengthen their presence in regulated international markets over the coming years.